



## **Starpharma Signs Agreement for Condom Coating Application of VivaGel™**

**Melbourne, Australia; 18 July 2007:** Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced that it has signed an agreement with a leading condom company in relation to the use of VivaGel™ as a condom coating.

The agreement includes a program of evaluation and development and also commercialisation rights covering condoms with VivaGel™ coatings within a specified geographical region. The condom company, whose name may not be disclosed for reasons of confidentiality, holds the leading market position within that region. The market in question is in the developed world, and ranks within the top five globally, measured by GDP.

The terms of the agreement were not disclosed.

"We are pleased to be able to report this solid progress in the commercialisation of VivaGel™ as a condom coating," commented Starpharma CEO, Dr Jackie Fairley. "This announcement reflects some of the growing momentum that we are achieving as we work to bring VivaGel™ as a condom coating to market."

VivaGel™ is in development as a vaginal microbicide, to prevent infection with HIV or genital herpes, under two FDA INDs\*. It has also been shown to have a potent contraceptive effect in animals. Its development as a condom coating represents a line extension to the standalone, applicator delivered vaginal microbicide.

*\*IND: Investigational New Drug Application*

---

### **About Starpharma:**

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel™ (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

In the pharmaceutical field Starpharma has additional specific programs in the areas of Drug Delivery and ADME Engineering™ (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).

More broadly the company is exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

SPL has a comprehensive IP portfolio that comprises more than 180 patents/applications issued and pending across 32 patent families - a unique level of IP concentration among nanotechnology companies.

**Dendrimers:** A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

**Microbicides:** A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function.

**American Depositary Receipts (ADRs):** Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.

**For further information:**

| <b>Media</b>                                                                                                            | <b>Starpharma</b><br><a href="http://www.starpharma.com">www.starpharma.com</a> |                                                                                        |
|-------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| <b>Rebecca Wilson</b><br><b>Buchan Consulting</b><br>Tel: +61 2 9237 2800<br>Mob: +61 417 382 391<br>rwilson@bcg.com.au | <b>Dr Jackie Fairley</b><br>Chief Executive Officer<br>+61 3 8532 2704          | <b>Ben Rogers</b><br>Company Secretary<br>+61 3 8532 2702<br>ben.rogers@starpharma.com |